In clinical trials, donanemab (Kisunla) modestly slowed the pace of thinking declines among patients in the early stages of the memory-robbing disease. But it also carried significant safety risks, including...
4.0 percent of seniors had received dementia diagnosis in 2022
Jun 13, 2024
An increase in the percentage with a dementia diagnosis was seen with increasing age; a decrease was seen with an increasing education level.
The 5-Cog paradigm improves diagnosis, management of dementia
Jun 11, 2024
A threefold improvement was seen in dementia care actions with the 5-Cog paradigm, a culturally adept cognitive detection tool.
FDA advisers support new Alzheimer’s drug
Jun 11, 2024
A US Food and Drug Administration advisory panel voted unanimously on Monday to recommend that the benefits of a new drug for Alzheimer’s outweigh its harms, which can include brain swelling and...